AMDL, Inc. engages in the development, manufacture, distribution, and sale of medical diagnostic products, generic pharmaceuticals, nutritional supplements, and cosmetics. The company offers DR-70, a non-invasive cancer blood test kit to detect lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, and pancreatic cancer; and MyHPV chip kit, a diagnostic product for screening cervical cancer through in-vitro genotype testing in women with human papilloma virus infection. It also involves in the manufacture and distribution of generic and homeopathic pharmaceutical products and supplements, and over-the-counter pharmaceutical products, as well as cosmetic products. AMDL primarily offers therapeutic and cosmetic human placental extract (HPE) based anti-aging products, including HPE solutions, Domperidone tablets, Compound Benzoic Acid and Camphor solution, Levofloxacin Lactate injection, Guyanling tablets, GS solution, GNS solution, and NaCL solution, as well as Diavitamin, Calcium, and Lysine tablets. In addition, the company owns a combination immunogene therapy technology that intends to build the body's immune system and destroy cancer cells. It sells its products directly to hospitals and retail stores, as well as indirectly to other customers through distributors worldwide. AMDL has a collaboration agreement with Mayo Clinic to conduct a clinical study for the validation of DR-70 test kit. The company was founded in 1988 and is based in Tustin, California.

Key Statistics

Closing Price	0.69
Volume	0
Volume Avg	155483
52 Week High	2.10
52 Week Low	0.43
PE	N/A
PE (group average)	78
EPS Year	0.00
EPS change Q/Q	1000%
EPS change Q/Q Yr ago	-10%
EPS change Q/Q next Q est	100%
EPS change Y/Y	1000%
REV change Q/Q	-72.16%
REV change Q/Q Yr ago	-6.9%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%